CVS Health initiated with a Market Perform at BMO Capital. BMO Capital analyst Matt Borsch initiated CVS Health with a Market Perform rating and a $58 price target. The analyst said that he is aware of the low valuation of the stock, but is “wary of further deterioration in the outlook given headwinds on CVS legacy businesses that have recently intensified,” and is not confident “the pressures will diminish next year.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.